Differential expression of TIM-3 in circulation and tumor microenvironment of colorectal cancer patients

Clin Immunol. 2020 Jun:215:108429. doi: 10.1016/j.clim.2020.108429. Epub 2020 Apr 19.

Abstract

T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) is an inhibitory immune checkpoint, which suppresses anti-tumor immune responses. TIM-3 expression on different immune cells in periphery and tumor microenvironment (TME) of colorectal cancer (CRC) patients has not been fully investigated. We found that TIM-3 was mainly expressed on monocytic myeloid cells (MMCs) and antigen-presenting cells (APCs) in circulation but was mainly expressed on T cells and APCs in the TME. Additionally, TIM-3- T cells co-expressed higher levels of PD-1 than TIM-3+ T cells in normal tissue. In contrast, TIM-3+ T cells in the TME showed significantly higher PD-1 expression. Interestingly, there was a trend towards increased levels of TIM-3+ APCs with disease stages; however, levels of TIM-3+ T cells were decreased with disease stages in the TME. This study shows the differential expression of TIM-3 on different immune cells in circulation and TME of CRC patients, and their associations with disease stages.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antigen-Presenting Cells / metabolism
  • Biomarkers, Tumor / blood
  • Biomarkers, Tumor / metabolism
  • Cells, Cultured
  • Colorectal Neoplasms / blood*
  • Colorectal Neoplasms / metabolism*
  • Hepatitis A Virus Cellular Receptor 2 / blood*
  • Humans
  • Monocytes / metabolism
  • Myeloid Cells / metabolism
  • Programmed Cell Death 1 Receptor / metabolism
  • T-Lymphocytes / metabolism
  • Tumor Microenvironment / physiology*

Substances

  • Biomarkers, Tumor
  • HAVCR2 protein, human
  • Hepatitis A Virus Cellular Receptor 2
  • Programmed Cell Death 1 Receptor